TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program
Werewolf Therapeutics Presents Preliminary Monotherapy Data from Phase 1/1b Clinical Trial Establishing Proof of Mechanism for WTX-124
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition
long